Page 113 - 《中国药房》2023年21期
P. 113

LI  J,YANG  J  B,WANG  Y  Z.  Applications  of  model-  patibility of Chuanxiong Rhizoma and Astragali Radix[J].
              informed  drug  development (MIDD)  on  new  drug  re‐  Chin Tradit Herb Drugs,2016,47(19):3463-3468.
              search and development[J]. Chin J Clin Pharmacol Ther,  [20]  潘洁,王昌权,李奎,等. 基于大鼠类风湿性关节炎模型
              2020,25(1):1-8.                                     建立黑骨藤的 PK-PD 模型[J]. 中草药,2020,51(20):
          [11]  WANG  X,LEE  W  Y  W,ZHOU  X  L,et  al.  A        5194-5200.
              pharmacodynamic-pharmacokinetic  (PD-PK)  study  on   PAN J,WANG C Q,LI K,et al. PK-PD model of Perip‐
              the  effects  of  Danshen (Salvia  miltiorrhiza)  on  mida-   loca  forrestii  based  on  rheumatiod  arthritis  rat  model[J].
              zolam,a  model  CYP3A  probe  substrate,in  the  rat[J].   Chin Tradit Herb Drugs,2020,51(20):5194-5200.
              Phytomedicine,2010,17(11):876-883.             [21]  谭兰芳,陈超,樊旭蕾,等. 基于PK-PD模型评价脑脉通
          [12]  FDA. Clinical drug interaction studies-study design,data   保护神经细胞的药效物质研究[J]. 中国中药杂志,2019,
              analysis,and clinical implications guidance for industry,  44(12):2588-2593.
              2017[EB/OL].(2017-10-25)[2023-08-04]. https://www.  TAN L F,CHEN C,FAN X L,et al. Study on pharmaco‐
              fda.gov/drugs/resources/clinical-drug-interaction-studies.  dynamic material basis of Naomaitong to protect neuronal
          [13]  BUDHA  N  R,LEABMAN  M,JIN  J Y,et  al.  Modeling   cells based on PK-PD model[J]. China J Chin Mater Med,
              and  simulation  to  support  phase  2  dose  selection  for   2019,44(12):2588-2593.
              RG7652,a fully human monoclonal antibody against pro‐  [22]  林力,刘建勋,张颖,等 . 中药复方双参通冠方的 PK/PD
              protein  convertase  subtilisin/kexin  type  9[J].  AAPS  J,  数据分析研究[J]. 世界科学技术-中医药现代化,2012,
              2015,17(4):881-890.                                 14(3):1583-1589.
          [14]  MANDEMA J W,SALINGER D H,BAUMGARTNER S            LIN L,LIU J X,ZHANG Y,et al. A PK/PD data proces-
              W,et  al.  A  dose-response  meta-analysis  for  quantifying   sing study on Chinese formulation of Shuang-Shen-Tong-
              relative  efficacy  of  biologics  in  rheumatoid  arthritis[J].   Guan  prescription[J].  Mod Tradit  Chin  Med  Mater  Med-
              Clin Pharmacol Ther,2011,90(6):828-835.             World Sci Technol,2012,14(3):1583-1589.
          [15]  CHAN  P,PESKOV  K,SONG  X  Y.  Applications  of    [23]  肖建鹏 . 基于网络药理学和 PK-PD 结合模型阐释酒女
              model-based meta-analysis in drug development[J]. Pharm   贞子抗骨质疏松增效机理[D]. 镇江:江苏大学,2022.
              Res,2022,39(8):1761-1777.                           XIAO J P. Synergistic mechanism of wine-processed Fruc‐
          [16]  李雪,王磊,卜睿臻,等. 基于模型引导的中药安全用药                        tus  Ligustri  Lucidi  against  osteoporosis  integrated  net‐
              的研究策略:中药定量毒理学[J]. 中草药,2023,54(2):                   work  pharmacology  and  PK-PD  model[D].  Zhenjiang:
              359-366.                                            Jiangsu University,2022.
              LI  X,WANG  L,BU  R  Z,et  al.  Model-guided  research   [24]  WANG  T  Y,LIN  S,LI  H,et  al.  A  stepwise  integrated
              strategies  for  safe  use  of  traditional  Chinese  medicine:  multi-system to screen quality markers of Chinese classic
              quantitative toxicology of traditional Chinese medicine[J].   prescription Qingzao jiufei decoction on the treatment of
              Chin Tradit Herb Drugs,2023,54(2):359-366.          acute lung injury by combining ‘network pharmacology-
          [17]  郑青山,陈凯先 . 基于模型的中药研发[J]. 世界科学技                     metabolomics-PK/PD modeling’[J]. Phytomedicine,2020,
              术-中医药现代化,2018,20(8):1269-1278.                      78:153313.
              ZHENG Q S,CHEN K X. Model-based Chinese medicine   [25]  毕聪,郑如文,黄海涛,等. 小柴胡颗粒基于网络药理学
              development[J]. Mod Tradit Chin Med Mater Med-World   的 组 方 配 伍 规 律 解 析 [J].  药 学 研 究 ,2020,39(9):
              Sci Technol,2018,20(8):1269-1278.                   504-513.
          [18]  CHENG D,LI W J,WANG L J,et al. Pharmacokinetics,  BI C,ZHENG R W,HUANG H T,et al. Network pharma‐
              pharmacodynamics,and  PKPD  modeling  of  curcumin  in   cology based analysis of the formula rules of Xiaochaihu
              regulating  antioxidant  and  epigenetic  gene  expression  in   granules[J]. J Pharm Res,2020,39(9):504-513.
              healthy  human  volunteers[J].  Mol  Pharm,2019,16(5):  [26]  寇俊萍,禹志领,龚树强,等. 小承气汤、厚朴大黄汤及厚
              1881-1889.                                          朴三物汤药理作用[J]. 中成药,2004,26(1):57-59.
          [19]  周惠芬,何昱,张宇燕,等. 川芎和黄芪有效部位组合给                        KOU J P,YU Z L,GONG S Q,et al. The actions of Xiao‐
              药后川芎嗪在脑缺血再灌注大鼠体内的 PK-PD 结合研                         chengqi decoction,Houpudahuang decoction and Houpu‐
              究[J]. 中草药,2016,47(19):3463-3468.                    sanwu decoction[J]. Chin Tradit Pat Med,2004,26(1):
              ZHOU H F,HE Y,ZHANG Y Y,et al. Study on PK-PD       57-59.
              combination  of  ligustrazine  in  cerebral  ischemia  reperfu‐  [27]  李晓萌,苏布达,黄志伟,等. 基于生理药动学模型预测
              sion rats after ig administration of effective parts in com‐  乌头碱在人体的药动学行为[J]. 中草药,2023,54(2):


          中国药房  2023年第34卷第21期                                              China Pharmacy  2023 Vol. 34  No. 21    · 2663 ·
   108   109   110   111   112   113   114   115   116   117   118